Sweden is one of Europe’s most scientifically distinguished clinical trial environments. With a population of approximately 10.5 million, world-class academic hospitals, and an unparalleled infrastructure of national population registries, Sweden offers sponsors a combination of regulatory efficiency, high-quality data, and internationally recognised investigators. The country is particularly strong in oncology, cardiovascular medicine, neurology, immunology, and rare diseases.
Sweden’s registry infrastructure is the envy of the global research community. The Swedish Total Population Register, the National Patient Register (covering inpatient data since 1964), the Swedish Cancer Register, the Prescribed Drug Register, and dozens of disease-specific quality registries provide a depth of longitudinal data that cannot be replicated elsewhere. For sponsors designing trials with registry-linked outcomes, long-term follow-up components, or real-world evidence sub-studies, Sweden is arguably the most valuable single-country option in Europe.
Sweden’s limitations are its relatively high costs and the fact that some major sites have lengthy internal contracting processes that can offset the speed advantage of regulatory approval. The MPA (Swedish Medical Products Agency) typically delivers decisions quickly, but sponsors should plan carefully for post-approval site activation to avoid unnecessary delays.
| Metric | Sweden |
| Competent Authority | Swedish Medical Products Agency (MPA / Läkemedelsverket) |
| Ethics Review | Swedish Ethical Review Authority (Etikprövningsmyndigheten) |
| Approval Timeline | ~30–45 days |
| Population | ~10.5 million |
| Strengths | Oncology, cardiovascular, neurology, immunology, rare diseases; exceptional registry infrastructure |
Sweden’s appeal combines fast regulatory processing, outstanding academic institutions, and a population registry infrastructure that is unique globally. Sponsors select Sweden when:
Sweden is not the right choice for sponsors who need to minimise costs or who require very large enrolment numbers from a single country. Its registry advantage is most valuable when the trial design is built to exploit it from the outset.
Sweden fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and submits all interventional clinical trial applications via CTIS. The national competent authority is the Swedish Medical Products Agency (MPA, Läkemedelsverket).
The ethics review is conducted by the Swedish Ethical Review Authority (Etikprövningsmyndigheten), a centralised national body established in 2019 that replaced the former regional ethics committee system. This centralisation has streamlined the ethics review process and improved consistency across Swedish trial applications.
The MPA and the Ethical Review Authority conduct their assessments in parallel under the EU CTR framework. Sweden can act as either the Reporting Member State or a Member State Concerned in multi-country submissions. Sponsors planning to use Swedish registry data must separately apply to Statistics Sweden (SCB) and/or the National Board of Health and Welfare (Socialstyrelsen) for data access; this process runs in parallel with the CTIS application but requires early planning.
Sweden’s regulatory process is fast. The main variable in Swedish start-up is not regulatory but post-approval contracting at sites, which can be slow at the larger university hospitals. Sponsors should plan for the following:
| Step | Estimated Timeline |
|---|---|
| CTIS submission and validation | 1–5 working days |
| MPA Part I assessment | ~30–45 days |
| Ethical Review Authority Part II assessment | ~30–45 days (parallel) |
| RFI response period (if applicable) | 12–31 days (clock stopped) |
| Site contract and budget negotiation | 8–20 weeks (variable by site) |
| Estimated total from submission to first patient | ~4–7 months |
Karolinska University Hospital and Sahlgrenska University Hospital have large research operations and multiple internal approval steps that can lengthen the post-regulatory contracting phase. Sponsors should initiate site feasibility and pre-contracting discussions well before CTIS submission to compress this phase.
Sweden’s clinical trial activity is anchored in four major university hospital networks:
Linköping University Hospital and Umeå University Hospital are additional academic sites with meaningful research output, particularly in specific specialties.
Sweden’s universal healthcare system (Sjukvård) channels patients through county council hospitals, ensuring that eligible patients at specialist academic centres are systematically referred from regional hospitals. This creates reliable patient flows to the major trial sites.
Sweden’s population registries enable pre-screening through data linkage, which is particularly valuable for rare diseases and for trials targeting specific patient sub-populations defined by biomarkers, comorbidities, or prior treatment. Swedish disease-specific quality registries – covering conditions from cancer to rheumatoid arthritis to heart failure – provide a level of detail and longitudinal coverage that few other countries can match.
Sweden’s regulatory speed is a genuine advantage, but the post-approval contracting phase at major academic hospitals requires careful management. The following reflects realistic ranges:
| Activity | Estimated Duration |
|---|---|
| Regulatory and ethics approval (CTIS) | 30–45 days |
| Site contract and budget negotiation | 8–20 weeks (variable) |
| Site initiation visit and staff training | 2–4 weeks |
| Registry data access approval (if applicable) | 8–20 weeks (parallel track) |
| First patient screened | ~4–7 months from submission |
Karolinska University Hospital’s contracting processes involve multiple layers of internal review and can take 16–20 weeks in some cases. Sponsors should treat this as a known variable and begin site engagement long before the regulatory submission is filed.
Sweden is an expensive country for clinical research, with Scandinavian salary levels and high hospital overhead costs. Per-patient costs for a Phase II oncology trial typically range from €22,000 to €48,000. Research nurse and coordinator costs, in particular, are significantly higher than in Central or Southern Europe.
Sweden’s national health system (Sjukvård) covers standard-of-care costs for trial participants, which partially offsets the per-patient charge to sponsors. Despite the high costs, Sweden’s data quality and registry infrastructure provide genuine value that is difficult to replicate elsewhere, and the total programme cost of a Swedish site contribution can be justified when the protocol is designed to leverage these advantages.
Sweden is most appropriate when investigator quality, registry access, and data standards outweigh cost considerations. It is a strong choice when:
APICES provides full-service CRO support for clinical trials in Sweden, including CTIS regulatory submissions, MPA and Etikprövningsmyndigheten liaison, site identification, feasibility, site management, and patient recruitment strategy. We have experience working with Sweden’s major university hospital sites and understand the contracting processes that can extend start-up timelines.
For sponsors planning registry-linked components, APICES can advise on data access applications to Statistics Sweden and the National Board of Health and Welfare, and on integrating these parallel processes into the overall trial timeline. We support sponsors from protocol design through final reporting, providing coordinated oversight across all Nordic and European countries in the programme.
How long does clinical trial approval take in Sweden?
Sweden delivers among the fastest clinical trial regulatory approvals in the EU. Under the EU CTR, applications are submitted via CTIS and the MPA (Läkemedelsverket) conducts the Part I assessment in parallel with the Etikprövningsmyndigheten’s Part II review. For a complete, well-prepared dossier, the combined decision typically falls within 30–45 days. The critical caveat for Sweden is post-approval contracting: while regulatory approval is fast, site contracts at major academic hospitals – particularly Karolinska – can take 8–20 weeks due to multiple internal approval layers. Sponsors should begin site engagement and pre-contracting discussions well before submitting to CTIS.
What are Sweden’s national population registries and how can they be used in clinical trials?
Sweden maintains an internationally unique suite of linked national health and population registries. The Total Population Register covers all Swedish residents; the National Patient Register covers all inpatient (and increasingly outpatient) contacts since 1964; the Swedish Cancer Register has tracked all cancer diagnoses since 1958; the Prescribed Drug Register covers all dispensed prescriptions since 2005; and over 100 disease-specific quality registries track conditions from heart failure to rheumatoid arthritis to paediatric leukaemia. All are linked by the Swedish personal identity number (personnummer). For clinical trials, this enables registry-linked endpoints (mortality, cancer incidence, hospitalisation), long-term safety follow-up after the active treatment phase, and pre-screening of patient populations using biomarker or treatment history criteria from registry data. Access requires separate application to Statistics Sweden and/or the National Board of Health and Welfare.
Is Sweden expensive for clinical trials?
Yes – Sweden is one of the more expensive European countries for clinical research. Scandinavian salary levels for research nurses, coordinators, and investigators significantly exceed those in Central or Southern Europe, and hospital overhead charges at academic sites are substantial. Per-patient costs for a Phase II oncology trial typically range from €22,000 to €48,000. Sweden’s national health system (Sjukvård) does cover standard-of-care costs for trial participants, which partially offsets the sponsor’s per-patient charge. The justification for including Sweden lies in data quality, registry access, and investigator excellence rather than cost efficiency.
What are the main clinical trial sites in Sweden?
The four principal university hospital networks are: Karolinska University Hospital in Stockholm (linked to Karolinska Institutet, one of the world’s top medical research universities; strong in oncology, haematology, neurology, and transplantation); Sahlgrenska University Hospital in Gothenburg (strong in cardiovascular, oncology, and respiratory); Uppsala University Hospital (historically central to Swedish Phase I and early-phase development; strong in oncology and endocrinology); and Skåne University Hospital across Lund and Malmö campuses (strong in rheumatology, oncology, and cardiovascular). Linköping University Hospital and Umeå University Hospital are additional academic sites relevant for specific indications.
Does Sweden use CTIS for clinical trial applications?
Yes. Sweden fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and all interventional clinical trial applications are submitted via the Clinical Trials Information System (CTIS). The Swedish Medical Products Agency (MPA, Läkemedelsverket) is the national competent authority. The Swedish Ethical Review Authority (Etikprövningsmyndigheten), a centralised body established in 2019, handles the ethics review. Sweden can serve as either the Reporting Member State or a Member State Concerned in multi-country submissions.
Why is Sweden particularly valuable for real-world evidence and registry-based studies?
Sweden offers a combination of characteristics that is unique globally: essentially complete population coverage through universal healthcare, a personal identity number (personnummer) that links data across all registries from birth, historical depth extending back decades in many registries, and highly standardised clinical documentation driven by national quality registry programmes. For sponsors designing trials where long-term outcomes matter – oncology overall survival, cardiovascular event rates, rare disease natural history – Swedish registry linkage provides a scientifically credible and cost-efficient means of capturing endpoints that would otherwise require extensive active follow-up. This is Sweden’s single greatest advantage over most other European countries.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
